The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

A key advisory group vows to base decisions on evidence, boost confidence in vaccines and protect health. Experts fear the opposite is happening.

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

Vaxcyte Inc. (NASDAQ:PCVX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

OP-ED. The US secretary of health has completely overhauled the national committee of vaccination experts, appointing ...

In this week’s edition of InnovationRx, we look at the health impact of the Republican spending bill, a startup that built a hospital in India to test its AI software, the impact of the vaccine panel ...

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60.

The CDC's Advisory Committee on Immunization Practices recommended the removal of the preservative thimerosal in seasonal influenza vaccines at their meeting.

The decision shows just how vaccine critics are beginning to shape official U.S. policy, public health officials told The Washington Post.